LifeMD Statistics
Total Valuation
LifeMD has a market cap or net worth of $218.29 million. The enterprise value is $205.85 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LifeMD has 43.31 million shares outstanding. The number of shares has increased by 22.27% in one year.
| Current Share Class | 43.31M |
| Shares Outstanding | 43.31M |
| Shares Change (YoY) | +22.27% |
| Shares Change (QoQ) | +1.76% |
| Owned by Insiders (%) | 13.93% |
| Owned by Institutions (%) | 39.86% |
| Float | 35.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 12.08 |
| PS Ratio | 1.04 |
| Forward PS | 0.88 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 10.76 |
| P/OCF Ratio | 10.08 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 10.15 |
Financial Position
The company has a current ratio of 0.83
| Current Ratio | 0.83 |
| Quick Ratio | 0.74 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.24 |
| Interest Coverage | -8.83 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -21.34% |
| Return on Capital (ROIC) | -85.54% |
| Revenue Per Employee | $914,972 |
| Profits Per Employee | -$121,392 |
| Employee Count | 211 |
| Asset Turnover | 3.41 |
| Inventory Turnover | 6.21 |
Taxes
In the past 12 months, LifeMD has paid $660,523 in taxes.
| Income Tax | 660,523 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.20% in the last 52 weeks. The beta is 1.42, so LifeMD's price volatility has been higher than the market average.
| Beta (5Y) | 1.42 |
| 52-Week Price Change | -36.20% |
| 50-Day Moving Average | 5.34 |
| 200-Day Moving Average | 7.01 |
| Relative Strength Index (RSI) | 41.16 |
| Average Volume (20 Days) | 738,553 |
Short Selling Information
The latest short interest is 5.97 million, so 13.78% of the outstanding shares have been sold short.
| Short Interest | 5.97M |
| Short Previous Month | 5.87M |
| Short % of Shares Out | 13.78% |
| Short % of Float | 16.78% |
| Short Ratio (days to cover) | 7.78 |
Income Statement
In the last 12 months, LifeMD had revenue of $193.06 million and -$25.61 million in losses. Loss per share was -$0.65.
| Revenue | 193.06M |
| Gross Profit | 173.06M |
| Operating Income | -19.33M |
| Pretax Income | -23.07M |
| Net Income | -25.61M |
| EBITDA | -17.97M |
| EBIT | -19.33M |
| Loss Per Share | -$0.65 |
Full Income StatementBalance Sheet
The company has $37.59 million in cash and $25.14 million in debt, giving a net cash position of $12.44 million or $0.29 per share.
| Cash & Cash Equivalents | 37.59M |
| Total Debt | 25.14M |
| Net Cash | 12.44M |
| Net Cash Per Share | $0.29 |
| Equity (Book Value) | -5.96M |
| Book Value Per Share | -0.18 |
| Working Capital | -10.30M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $21.66 million and capital expenditures -$1.37 million, giving a free cash flow of $20.28 million.
| Operating Cash Flow | 21.66M |
| Capital Expenditures | -1.37M |
| Free Cash Flow | 20.28M |
| FCF Per Share | $0.47 |
Full Cash Flow StatementMargins
Gross margin is 89.64%, with operating and profit margins of -10.01% and -11.66%.
| Gross Margin | 89.64% |
| Operating Margin | -10.01% |
| Pretax Margin | -11.15% |
| Profit Margin | -11.66% |
| EBITDA Margin | -9.31% |
| EBIT Margin | -10.01% |
| FCF Margin | 10.51% |
Dividends & Yields
LifeMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.27% |
| Shareholder Yield | -22.27% |
| Earnings Yield | -11.73% |
| FCF Yield | 9.29% |
Analyst Forecast
The average price target for LifeMD is $12.13, which is 140.68% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.13 |
| Price Target Difference | 140.68% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 27.92% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on October 14, 2020. It was a reverse split with a ratio of 0.2:1.
| Last Split Date | Oct 14, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.2:1 |
Scores
LifeMD has an Altman Z-Score of -0.66 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.66 |
| Piotroski F-Score | 5 |